Yingxia Liu

TL;DR: The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients and offer vital clinical information during the course of SARS-CoV-2 infection.

TL;DR: In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status, and these observations require evaluation in clinical trials.

TL;DR: The epidemiological, clinical, laboratory, and radiological characteristics, as well as potential biomarkers for predicting disease severity in 2019-nCoV-infected patients in Shenzhen, China, suggest a number of potential diagnosis biomarkers and angiotensin receptor blocker drugs for potential repurposing treatment of 2019- nCoV infection.

TL;DR: In this open-label nonrandomized control study, FPV showed significantly better treatment effects on COVID-19 in terms of disease progression and viral clearance; if causal, these results should be important information for establishing standard treatment guidelines to combat the SARS-CoV-2 infection.

TL;DR: In isolation of four human-origin monoclonal antibodies from a convalescent patient, all of which display neutralization abilities, a therapeutic study in a mouse model validated that these antibodies can reduce virus titers in infected lungs.